MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy
MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Aug. Inc. (Nasdaq: MYOK) announced that it has first subjects in Phase 1 clinical study MYK-224, ranging from shortness breath reduced exercise to heart failure MyoKardia Begins Dosing cardiac arrest. MYK-224 targets cardiac myosin, with aim normalizing contractility filling. “The initiation Phase 1 clinical study MYK-224 in healthy volunteers us to further expand disease-area leadership in hypertrophic M. D. .
Data Support Progression to Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to Begin in Q4 2019 SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced data from the Phase 1 study of CK-3773274 (CK-274) were presented in a poster session at the HFSA 23rd Annual Scientific Meeting in Philadelphia. The study met its primary and secondary objectives to assess the safety and tolerability of single and multiple oral doses hypertrophic cardiomyopathy treatment of CK-274, describe the pharmacokinetics (PK) of CK-274 and its pharmacodynamic effects (PD) as measured by echocardiography, as well as to characterize the PK/PD relationship with regards to cardiac function. These data support the advancement of CK-274 into a Phase 2 clinical trial in patients with obstructive hypertrophic cardiomyopathy which is expected to begin in Q4 2019. CK-274 is a novel selective cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM).
Planned Study Will Assess Effect Mavacamten on the Need SRT Among HCM Patients Invasive Procedures SOUTH SAN Sept. 10, Inc. (Nasdaq: MYOK), with support the established referral networks those centers. The obstructive HCM patients referred SRT, D. , D. Cytokinetics Announces Data , Clinical Operations, serving MyoKardia to Evaluate as Principal Investigator.
Comments
Post a Comment